作者
C Bridel, MJA Koel‐Simmelink, L Peferoen, C Derada Troletti, S Durieux, R Gorter, E Nutma, P Gami, E Iacobaeus, L Brundin, J Kuhle, H Vrenken, J Killestein, SR Piersma, TV Pham, HE De Vries, S Amor, CR Jimenez, CE Teunissen
发表日期
2018/6
期刊
Neuropathology and applied neurobiology
卷号
44
期号
4
页码范围
404-416
简介
Aims
Cell matrix modulating protein SPARCL‐1 is highly expressed by astrocytes during CNS development and following acute CNS damage. Applying NanoLC‐MS/MS to CSF of RRMS and SPMS patients, we identified SPARCL‐1 as differentially expressed between these two stages of MS, suggesting a potential as CSF biomarker to differentiate RRMS from SPMS and a role in MS pathogenesis.
Methods
This study examines the potential of SPARCL‐1 as CSF biomarker discriminating RRMS from SPMS in three independent cohorts (n = 249), analyses its expression pattern in MS lesions (n = 26), and studies its regulation in cultured human brain microvasculature endothelial cells (BEC) after exposure to MS‐relevant inflammatory mediators.
Results
SPARCL‐1 expression in CSF was significantly higher in SPMS compared to RRMS in a Dutch cohort of 76 patients. This finding was not replicated in 2 …
学术搜索中的文章
C Bridel, MJA Koel‐Simmelink, L Peferoen… - Neuropathology and applied neurobiology, 2018